B-cell depletion for chronic fatigue after infection
Treatments studied
Part of Blood & lymphatic, Bones, joints & muscles, Brain & nervous system, Genetic & congenital, Infections, Lungs & breathing clinical trials.
This trial tests whether a treatment that removes certain immune cells (called B cells) can help people with ME/CFS (chronic fatigue syndrome) that started after an infection. It is for people who have already tried a procedure called immunoadsorption and felt better but then got worse again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 65 years old.
- You have been diagnosed with post-infectious ME/CFS (chronic fatigue syndrome) with severe post-exertional malaise (worsening of symptoms for more than 14 hours after activity).
- You have elevated beta-2 adrenergic autoantibodies (a type of antibody in your blood).
- You have had immunoadsorption treatment (a blood filtering procedure) at least 6 months ago, and you had a clear improvement (at least 10 points on a physical function scale) followed by a relapse.
- Your typical activity level is between 30 and 60 on the Bell disability scale (moderate to severe symptoms).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study observes how a blood-cleaning treatment called immunoadsorption works in patients with ME/CFS (severe fatigue condition) who have specific immune markers. Researchers will track whether this treatment helps reduce symptoms and improve daily functioning.
This study tests whether a medication called aripiprazole can help with long-lasting symptoms like brain fog, fatigue, or mood changes that start after an infection (such as COVID-19). It aims to see if this treatment improves these neuropsychiatric symptoms.
This study looks at how chronic infections and inflammation affect people with ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) compared to healthy people. Researchers want to understand what causes symptoms and find better ways to help.
This study tests whether a lab-made antibody (sipavibart) can reduce Long COVID symptoms. It is for people who developed Long COVID after a confirmed COVID infection and still have moderate to severe fatigue and other ME/CFS-like symptoms.
This trial tests if filtering certain antibodies from the blood can help people with long COVID who experience post-exertional malaise (PEM) and reduced function. It aims to see if this treatment reduces symptoms and improves daily life.
This trial tests whether immune-modulating treatments can help people with long covid, especially those with ongoing heart, cough, or fatigue symptoms. It aims to see if calming the immune system reduces symptoms and improves daily life.
Hear when a new Post-acute Infectious Syndrome (PAIS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.